Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods (2023 - 2026)

Krystal Biotech's Finished Goods history spans 4 years, with the latest figure at $12.4 million for Q1 2026.

  • On a quarterly basis, Finished Goods rose 109.53% to $12.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.4 million, a 109.53% increase, with the full-year FY2025 number at $9.3 million, up 338.05% from a year prior.
  • Finished Goods hit $12.4 million in Q1 2026 for Krystal Biotech, up from $9.3 million in the prior quarter.
  • Over the last five years, Finished Goods for KRYS hit a ceiling of $12.4 million in Q1 2026 and a floor of $161000.0 in Q1 2024.
  • Historically, Finished Goods has averaged $4.4 million across 4 years, with a median of $2.7 million in 2024.
  • The widest YoY moves for Finished Goods: up 3563.35% in 2025, down 4.03% in 2025.
  • Tracing KRYS's Finished Goods over 4 years: stood at $627000.0 in 2023, then skyrocketed by 239.07% to $2.1 million in 2024, then surged by 338.05% to $9.3 million in 2025, then surged by 32.7% to $12.4 million in 2026.
  • Business Quant data shows Finished Goods for KRYS at $12.4 million in Q1 2026, $9.3 million in Q4 2025, and $7.3 million in Q3 2025.